TMHC(TMHC)
TMHC
Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.
Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.
| Metric | FY2026E | FY2027E |
|---|---|---|
| Revenue Avg | $6.64B | $7.15B |
| Low | $6.53B | $7.08B |
| High | $6.73B | $7.22B |
| EBITDA Avg | $906M | $976M |
| Low | $891M | $966M |
| High | $919M | $985M |
| EBIT Avg | $925M | $997M |
| Low | $911M | $987M |
| High | $939M | $1.01B |
| Net Income Avg | $538M | $657M |
| Low | $532M | $637M |
| High | $543M | $676M |
| EPS Avg | $5.29 | $6.54 |
| Low | $5.28 | $6.33 |
| High | $5.39 | $6.72 |
| Analysts (Rev / EPS) | 5 / 3 | 5 / 4 |
| Metric | Q2 2026 | Q3 2026 | Q4 2026 | Q1 2027 | Q2 2027 | Q3 2027 | Q4 2027 |
|---|---|---|---|---|---|---|---|
| Revenue Avg | $1.54B | $1.78B | $1.94B | $1.39B | $1.73B | $1.85B | $2.14B |
| Low | $1.45B | $1.72B | $1.82B | $1.31B | $1.63B | $1.75B | $2.01B |
| High | $1.63B | $1.84B | $2.05B | $1.48B | $1.83B | $1.96B | $2.26B |
| EBITDA Avg | $210M | $243M | $264M | $190M | $236M | $253M | $291M |
| Low | $198M | $234M | $249M | $179M | $222M | $238M | $274M |
| High | $222M | $251M | $279M | $201M | $250M | $268M | $308M |
| EBIT Avg | $214M | $249M | $270M | $194M | $241M | $259M | $298M |
| Low | $202M | $239M | $254M | $183M | $227M | $243M | $280M |
| High | $227M | $256M | $285M | $206M | $255M | $274M | $315M |
| Net Income Avg | $111M | $140M | $165M | $112M | $149M | $176M | $216M |
| Low | $110M | $130M | $152M | $103M | $138M | $163M | $200M |
| High | $112M | $151M | $177M | $120M | $161M | $189M | $233M |
| EPS Avg | $1.14 | $1.44 | $1.69 | $1.14 | $1.53 | $1.81 | $2.22 |
| Low | $1.13 | $1.33 | $1.56 | $1.06 | $1.42 | $1.67 | $2.05 |
| High | $1.15 | $1.55 | $1.81 | $1.23 | $1.65 | $1.94 | $2.38 |
| Analysts (Rev / EPS) | 4 / 3 | 4 / 3 | 3 / 1 | 3 / 1 | 2 / 1 | 2 / 1 | 3 / 1 |